IgM抗链霉亲和素抗体导致类似生物素的干扰引发假性甲亢
本文报道两例因IgM抗链霉亲和素抗体干扰免疫检测而表现为假性甲亢的患者。患者1为77岁女性,服卡比马唑多年但甲功不提示甲减;患者2为25岁女性,游离甲状腺素升高但促甲状腺素最低仅0.17 mIU/L。干扰表现为夹心法假性偏低、竞争法假性偏高,预孵育链霉亲和素微粒可消除干扰。
要点
- 当临床表现与实验室结果不符时,应排除分析干扰。
- IgM抗链霉亲和素抗体可模拟生物素干扰,导致夹心法假性偏低、竞争法假性偏高。
- 一种免疫检测发现干扰时,应警惕其他检测也可能受影响。
核心结论
- 两例表观甲亢由IgM抗链霉亲和素抗体引起的分析干扰所致。
- 一种免疫检测上发现的分析干扰应提示其他结果也可能受影响。
- 抗链霉亲和素抗体的干扰模式类似于摄入生物素,但干扰程度因检测方法和患者而异。
研究设计与样本
- 两例病例报告,对患者血清进行免疫检测干扰特征分析。
主要发现
- 患者1为77岁女性,服卡比马唑多年但甲功不提示甲减。
- 患者2为25岁女性,游离甲状腺素升高,促甲状腺素最低记录为0.17 mIU/L。
- 两例用替代方法检测甲功结果显著不同。
- 夹心法(如促甲状腺素、促卵泡激素、肌钙蛋白T、β-人绒毛膜促性腺激素)假性偏低,竞争法(如游离甲状腺素、游离三碘甲状腺原氨酸、TSH结合抑制免疫球蛋白)假性偏高。
- 预孵育链霉亲和素微粒可消除干扰,但两例均未服用生物素;从血清中分离出约100 kDa的高亲和力IgM抗链霉亲和素抗体。
关键数值与推荐
- 患者2促甲状腺素最低记录为0.17 mIU/L。
- 干扰物为约100 kDa的IgM免疫球蛋白,对链霉亲和素有高亲和力。
- 夹心法假性偏低,竞争法假性偏高;预孵育链霉亲和素微粒可消除干扰。
临床怎么用
- 临床表现与实验室结果不符时,应考虑分析干扰的可能。
- 对一种免疫检测发现的干扰应排查其他可能受影响的检测。
- 抗链霉亲和素抗体干扰模式类似生物素干扰,但程度因检测和患者而异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exclusion of analytical interference is important when there is discrepancy between clinical and laboratory findings. However, interferences on immunoassays are often mistaken as isolated laboratory artefacts. The mechanism of a rare cause of interference in two patients that caused erroneous thyroid function tests, and also affects many other biotin dependent immunoassays, was characterized and reported. PATIENT FINDINGS: Patient 1 was a 77-year-old female with worsening fatigue while taking carbimazole over several years. Her thyroid function tests, however, were not suggestive of hypothyroidism. Patient 2 was a 25-year-old female also prescribed carbimazole for apparent primary hyperthyroidism. Despite an elevated free thyroxine, the lowest thyrotropin on record was 0.17 mIU/L. In both cases, thyroid function tests performed by an alternative method were markedly different. Further characterization of both patients' serum demonstrated analytical interference on many immunoassays using the biotin-streptavidin interaction. Sandwich assays (e.g., thyrotropin, follicle-stimulating hormone, troponin T, beta-human chorionic gonadotropin) were falsely low, while competitive assays (e.g., free thyroxine, free triiodothyronine, TSH binding inhibitory immunoglobulin) were falsely high. Pre-incubation of serum with streptavidin microparticles removed the analytical interference, initially suggesting the cause of interference was biotin. However, neither patient had been taking biotin. Instead, a ∼100 kDa immunoglobulin M (IgM) immunoglobulin with high affinity to streptavidin was isolated from each patient's serum. The findings confirm IgM anti-streptavidin antibodies as the cause of analytical interference. SUMMARY: Two patients with apparent hyperthyroidism as a result of analytical interference caused by IgM anti-streptavidin antibodies are described. CONCLUSION: Analytical interference identified on one immunoassay should raise the possibility of other affected results. Characterization of interference may help to identify other potentially affected immunoassays. In the case of anti-streptavidin antibodies, the pattern of interference mimics that due to biotin ingestion. However, the degree of interference varies between individual assays and between patients.
引用
- Lam L, Bagg W, Smith G, et al. Apparent Hyperthyroidism Caused by Biotin-Like Interference from IgM Anti-Streptavidin Antibodies. Thyroid. 2018. PMID: 29808739. doi:10.1089/thy.2017.0673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。